Ocular Therapeutix to Showcase Innovations at Upcoming Events
This September, Ocular Therapeutix, Inc. (NASDAQ: OCUL) is set to connect with the investment community by participating in two major investor conferences. Based in Massachusetts, this biopharmaceutical company is committed to transforming vision treatments with advanced therapies for retinal diseases and various eye conditions.
Fireside Chats and Presentations
On Tuesday, September 10, 2024, Ocular will take part in the Baird 2024 Global Healthcare Conference, featuring a fireside chat that begins at 12:50 PM ET. The following day, Wednesday, September 11, 2024, Ocular will also be present at the H.C. Wainwright 26th Annual Global Investment Conference, where their fireside chat is scheduled to start at 8:30 AM ET. Both events will be held in New York and are expected to highlight Ocular's exciting developments.
Accessing the Webcasts
If you're interested in Ocular's updates, you can tune in to the live webcast of the H.C. Wainwright fireside chat by visiting the Investors section of the Company’s official website.
About Ocular Therapeutix, Inc.
Ocular Therapeutix is focused on improving vision through the development and commercialization of groundbreaking therapies aimed at retinal diseases. One of its flagship product candidates, AXPAXLI™ (also referred to as OTX-TKI), utilizes the proprietary ELUTYX™ bioresorbable hydrogel formulation technology and is currently in Phase 3 clinical trials for the treatment of wet age-related macular degeneration.
Innovative Pipeline of Therapies
The company boasts a strong pipeline that leverages ELUTYX technology not only for AXPAXLI but also for DEXTENZA™, an FDA-approved corticosteroid designed to treat ocular inflammation and pain following surgery, as well as allergic conjunctivitis. Furthermore, Ocular is progressing with PAXTRAVA™, an intracameral implant of travoprost that has successfully completed a Phase 2 clinical trial aimed at open-angle glaucoma and ocular hypertension.
Stay Connected with Ocular
To stay informed about the latest updates and insights into the company's advancements, Ocular Therapeutix encourages stakeholders to follow their journey on their official website, LinkedIn, and X platforms.
Frequently Asked Questions
What is Ocular Therapeutix, Inc. known for?
Ocular Therapeutix, Inc. specializes in creating innovative therapies for retinal diseases and other eye conditions using its proprietary technologies.
When are the investor conferences taking place?
The investor conferences are set for September 10 and September 11, 2024.
How can I access the live webcast of the presentations?
You can access the live webcast for the H.C. Wainwright fireside chat through the Investors section of Ocular Therapeutix’s website.
What products are currently in development by Ocular Therapeutix?
The current development pipeline features AXPAXLI™ for wet AMD and PAXTRAVA™ for open-angle glaucoma, both utilizing the innovative ELUTYX technology.
How does Ocular Therapeutix contribute to the healthcare industry?
Ocular Therapeutix aims to enhance patient outcomes and improve quality of life by focusing on innovative therapeutics for ocular conditions, ultimately providing better vision solutions.